Considering that a sustained-release PGI2 receptor agonist, ONO-1301-MS, improves motor function and prevents loss of motor neurons in G93A mice [51], the selective inhibition of PGE2 production by mPGES-1 is more beneficial for the treatment of ALS than the non-selective inhibition of PG production by COX-2. Here, PTGS2 is linked to amyotrophic lateral sclerosis.